Evidence-Based Reviews

Using atypicals for patients without psychosis: The strength of evidence varies with the diagnosis

Current Psychiatry. 2002 October;1(10):54-64

References

1. Dally P, Sargant W. A new treatment of anorexia nervosa. BMJ 1960;1:1770-3.

2. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatr Scand 1982;66:445-50.

3. Hanson L. Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999;175:592.-

4. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry 1999;11(4):233-6.

5. American Academy of Child and Adolescent Psychiatry. AACAP official action: practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 1997;36:69-84.

6. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141(10):1195-1202.

7. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40(10):1206-14.

8. Zuddis A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10(2):79-90.

9. Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 1999;9(4):273-6.

10. McDougle CJ, Homes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-93.

11. McCracken JT, McGough J, et al. Risperidone in children with autism and serious behavioral problems. Research Units on Pediatric Psychopharmacology Autism Network. N Eng J Med. 2002;347(5):314-21.

12. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.

13. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-94.

14. Kemner C, van Engeland H, Tuynman-Qua H. An open-label study of olanzapine in children with pervasive development disorder. Eur Neuropsychopharmacol 1999;9(suppl 5):S287-S288.

15. Kemner C, van Engeland H, Tuynman-Qua H. An open-label study of olanzapine in children with PDD. Schizophr Res 2000;41(1, suppl 1):194.-

16. Scahill L, Chappell PB, King RA, et al. Pharmacologic treatment of tic disorders. Child Adolesc Clin North Am 2000;9:99-117.

17. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-9.

18. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;50:912-24.

19. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison of hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984;41:650-6.

20. Findling RL, McNamara NK, Branicky LA, et al. A double blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39:509-16.

21. Aman MG, Findling RL, Derivan A, et al. Safety and efficacy of risperidone in children with significant conduct problems and borderline IQ or mental retardation. Brussels, Belgium: 22nd Collegium Internationale Neuro-psychopharmacologicum Congress, July 2000.

22. Turgay A, Snyder R, Fishman S, et al. and the Conduct Research Group. Risperidone versus placebo for conduct and other disruptive behavior disorders in children with subaverage IQ (poster presentation). Victoria, British Columbia, Canada: Canadian Psychiatric Association annual meeting, October 2000.

23. Holford LE, Peter E, Van der Walt A. Risperidone for behavior disorders in children with mental retardation (poster presentation). New York: American Academy of Child and Adolescent Psychiatry annual meeting, October 2000.

24. La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eating Disord 2000;27:363-6.